The future of life sciences is connected, AI-driven, and patient-centric

The pandemic magnified the life sciences industry’s position as an integral part of the end-to-end healthcare value chain. Stakeholders from payers to providers to patients expect connectivity and real-time communication, which can be achieved through more innovative digital health offerings and more sophisticated forms of artificial intelligence. Regarding AI, life sciences organizations have been out ahead of the pack long before the current excitement around the technology, with strategic uses across research & development and clinical decision support. There is also excitement around precision medicine, which is poised to experience explosive growth as companies shift a greater percentage of their portfolios to these groundbreaking treatments.    

In this paper we offer a deeper dive into the drivers of change mentioned above and offer guidance across four strategic imperatives that will help organizations win in this new, hyper-connected healthcare marketplace:

• Design tech-enabled, customer-centric experiences
• Develop AI partnerships for faster time to market
• Rethink the supply chain
• Manage cyber-risks 

Organizations that analyze where they stand on the maturity curve in relation to these signals of change and strategic imperatives will be better prepared to shape the future of life sciences.

To learn more about KPMG Precision Medicine Insights database, visit our website.